Esperion Therapeutics (NASDAQ:ESPR) Upgraded at StockNews.com

StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a report issued on Thursday.

Several other research firms have also recently issued reports on ESPR. Needham & Company LLC dropped their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Stock Up 8.1 %

ESPR opened at $2.28 on Thursday. Esperion Therapeutics has a 52 week low of $0.87 and a 52 week high of $3.40. The business has a 50 day moving average price of $1.91 and a two-hundred day moving average price of $2.13. The company has a market cap of $447.39 million, a PE ratio of -3.56 and a beta of 0.96.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to analysts’ expectations of $51.90 million. As a group, sell-side analysts expect that Esperion Therapeutics will post -0.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds have recently bought and sold shares of the stock. BOKF NA acquired a new position in shares of Esperion Therapeutics in the second quarter valued at approximately $26,000. Traphagen Investment Advisors LLC acquired a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Xponance Inc. purchased a new position in Esperion Therapeutics in the second quarter valued at approximately $28,000. CVI Holdings LLC acquired a new position in Esperion Therapeutics during the first quarter valued at approximately $37,000. Finally, Sivia Capital Partners LLC acquired a new position in Esperion Therapeutics during the second quarter valued at approximately $44,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.